Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-DFO-C14 + 161Tb-DOTA-C14
- Development stage
- Preclinical
- Lead developer
- NYU Grossman School of Medicine
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-DFO-C14 + 161Tb-DOTA-C14 is a preclinical theranostic radiopharmaceutical combination targeting Mucin 13 (MUC13) for the staging and treatment of colorectal cancer (CRC). The diagnostic component, 89Zr-DFO-C14, consists of the MUC13-targeting monoclonal antibody clone C14 conjugated to deferoxamine (DFO) and radiolabeled with zirconium-89 (89Zr) for positron emission tomography (PET) imaging to assess target density and select patients. The therapeutic component, 161Tb-DOTA-C14, consists of the C14 antibody conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and radiolabeled with terbium-161 (161Tb), a dual beta- and Auger electron-emitting radionuclide, for targeted radiopharmaceutical therapy (RPT) and SPECT imaging. This theranostic pair is being developed by researchers at institutions including the University of Texas MD Anderson Cancer Center.
- Other names
- 89Zr-C14 + 161Tb-C1489Zr-DFO-C14 and 161Tb-DOTA-C1489Zr-labeled C14 + 161Tb-labeled C14
02
Targets
MUC13 (Mucin-13)
Beyond the preview
Go deeper on 89Zr-DFO-C14 + 161Tb-DOTA-C14.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-DFO-C14 + 161Tb-DOTA-C14.